Jay Birnbaum
Director/Board Member at SONOMA PHARMACEUTICALS, INC.
Net worth: 918 $ as of 2024-04-29
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
John Gordon Foulkes | M | - |
Lipidio Pharmaceuticals, Inc.
Lipidio Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lipidio Pharmaceuticals, Inc. develops and manufactures medicines. It focuses on developing drugs to treat diseases associated with excess body fat and its lead program, GDD3898, is being investigated for the treatment of nonalcoholic steatohepatitis (NASH) and Prader Willi syndrome (PWS), an orphan disease, and anti-psychotic drug induced weight gain (AIWG). The company was founded by Jay Edward Birnbaum and is headquartered San Diego, CA.
Thirona Bio, Inc.
Thirona Bio, Inc. Pharmaceuticals: MajorHealth Technology Thirona Bio, Inc. is an American biopharmaceutical company that focuses on developing drugs for fibrotic diseases. Thirona Bio is based in an undisclosed location. The private company's target indications include scleroderma, keloid scars, and certain cancers where there are no effective therapies. The company's unique approach uses a potent, topically applied drug to inhibit TGF-? "locally," minimizing the potential risk of systemic toxicity. The company was founded by John Gordon Foulkes, Jay Edward Birnbaum, K. George Mooney, and David A. Bullough, with John Gordon Foulkes serving as the CEO since incorporation. | - |
John Poggetto | M | 53 | 20 years | |
Mark T. Taylor | M | - |
Hallux, Inc.
Hallux, Inc. Pharmaceuticals: MajorHealth Technology Hallux, Inc. provides pharmaceutical services. It develops a new terbinafine dosage form and subungual route of administration for the treatment of onychomycosis. The company was founded by Mark T. Taylor, Jay Edward Birnbaum, Hendrik Arend Kroon and Robert Orr in 2012 and is headquartered in Laguna Hills, CA. | 12 years |
Bruce Thornton | M | 60 | 20 years | |
David A. Bullough | M | - |
Lipidio Pharmaceuticals, Inc.
Lipidio Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lipidio Pharmaceuticals, Inc. develops and manufactures medicines. It focuses on developing drugs to treat diseases associated with excess body fat and its lead program, GDD3898, is being investigated for the treatment of nonalcoholic steatohepatitis (NASH) and Prader Willi syndrome (PWS), an orphan disease, and anti-psychotic drug induced weight gain (AIWG). The company was founded by Jay Edward Birnbaum and is headquartered San Diego, CA.
Thirona Bio, Inc.
Thirona Bio, Inc. Pharmaceuticals: MajorHealth Technology Thirona Bio, Inc. is an American biopharmaceutical company that focuses on developing drugs for fibrotic diseases. Thirona Bio is based in an undisclosed location. The private company's target indications include scleroderma, keloid scars, and certain cancers where there are no effective therapies. The company's unique approach uses a potent, topically applied drug to inhibit TGF-? "locally," minimizing the potential risk of systemic toxicity. The company was founded by John Gordon Foulkes, Jay Edward Birnbaum, K. George Mooney, and David A. Bullough, with John Gordon Foulkes serving as the CEO since incorporation. | - |
Nancy Hutson | M | 74 |
Lipidio Pharmaceuticals, Inc.
Lipidio Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lipidio Pharmaceuticals, Inc. develops and manufactures medicines. It focuses on developing drugs to treat diseases associated with excess body fat and its lead program, GDD3898, is being investigated for the treatment of nonalcoholic steatohepatitis (NASH) and Prader Willi syndrome (PWS), an orphan disease, and anti-psychotic drug induced weight gain (AIWG). The company was founded by Jay Edward Birnbaum and is headquartered San Diego, CA.
Thirona Bio, Inc.
Thirona Bio, Inc. Pharmaceuticals: MajorHealth Technology Thirona Bio, Inc. is an American biopharmaceutical company that focuses on developing drugs for fibrotic diseases. Thirona Bio is based in an undisclosed location. The private company's target indications include scleroderma, keloid scars, and certain cancers where there are no effective therapies. The company's unique approach uses a potent, topically applied drug to inhibit TGF-? "locally," minimizing the potential risk of systemic toxicity. The company was founded by John Gordon Foulkes, Jay Edward Birnbaum, K. George Mooney, and David A. Bullough, with John Gordon Foulkes serving as the CEO since incorporation. | - |
K. George Mooney | M | - |
Thirona Bio, Inc.
Thirona Bio, Inc. Pharmaceuticals: MajorHealth Technology Thirona Bio, Inc. is an American biopharmaceutical company that focuses on developing drugs for fibrotic diseases. Thirona Bio is based in an undisclosed location. The private company's target indications include scleroderma, keloid scars, and certain cancers where there are no effective therapies. The company's unique approach uses a potent, topically applied drug to inhibit TGF-? "locally," minimizing the potential risk of systemic toxicity. The company was founded by John Gordon Foulkes, Jay Edward Birnbaum, K. George Mooney, and David A. Bullough, with John Gordon Foulkes serving as the CEO since incorporation. | - |
Robert Orr | M | - |
Hallux, Inc.
Hallux, Inc. Pharmaceuticals: MajorHealth Technology Hallux, Inc. provides pharmaceutical services. It develops a new terbinafine dosage form and subungual route of administration for the treatment of onychomycosis. The company was founded by Mark T. Taylor, Jay Edward Birnbaum, Hendrik Arend Kroon and Robert Orr in 2012 and is headquartered in Laguna Hills, CA. | 12 years |
John Mclaughlin | M | 76 | 11 years | |
Daniel Petree | M | 68 |
Lipidio Pharmaceuticals, Inc.
Lipidio Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lipidio Pharmaceuticals, Inc. develops and manufactures medicines. It focuses on developing drugs to treat diseases associated with excess body fat and its lead program, GDD3898, is being investigated for the treatment of nonalcoholic steatohepatitis (NASH) and Prader Willi syndrome (PWS), an orphan disease, and anti-psychotic drug induced weight gain (AIWG). The company was founded by Jay Edward Birnbaum and is headquartered San Diego, CA. | - |
Lynda Kay Chandler | F | - |
Thirona Bio, Inc.
Thirona Bio, Inc. Pharmaceuticals: MajorHealth Technology Thirona Bio, Inc. is an American biopharmaceutical company that focuses on developing drugs for fibrotic diseases. Thirona Bio is based in an undisclosed location. The private company's target indications include scleroderma, keloid scars, and certain cancers where there are no effective therapies. The company's unique approach uses a potent, topically applied drug to inhibit TGF-? "locally," minimizing the potential risk of systemic toxicity. The company was founded by John Gordon Foulkes, Jay Edward Birnbaum, K. George Mooney, and David A. Bullough, with John Gordon Foulkes serving as the CEO since incorporation. | - |
Philippe Weigerstorfer | M | 64 | 6 years | |
Jerome Dvonch | M | 56 | 4 years | |
Amy Trombly | F | 57 | 5 years | |
William Forbes | M | 62 |
Hallux, Inc.
Hallux, Inc. Pharmaceuticals: MajorHealth Technology Hallux, Inc. provides pharmaceutical services. It develops a new terbinafine dosage form and subungual route of administration for the treatment of onychomycosis. The company was founded by Mark T. Taylor, Jay Edward Birnbaum, Hendrik Arend Kroon and Robert Orr in 2012 and is headquartered in Laguna Hills, CA. | 6 years |
John P. Montana | M | - |
Thirona Bio, Inc.
Thirona Bio, Inc. Pharmaceuticals: MajorHealth Technology Thirona Bio, Inc. is an American biopharmaceutical company that focuses on developing drugs for fibrotic diseases. Thirona Bio is based in an undisclosed location. The private company's target indications include scleroderma, keloid scars, and certain cancers where there are no effective therapies. The company's unique approach uses a potent, topically applied drug to inhibit TGF-? "locally," minimizing the potential risk of systemic toxicity. The company was founded by John Gordon Foulkes, Jay Edward Birnbaum, K. George Mooney, and David A. Bullough, with John Gordon Foulkes serving as the CEO since incorporation. | - |
Raksha Shah | M | - |
Lipidio Pharmaceuticals, Inc.
Lipidio Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lipidio Pharmaceuticals, Inc. develops and manufactures medicines. It focuses on developing drugs to treat diseases associated with excess body fat and its lead program, GDD3898, is being investigated for the treatment of nonalcoholic steatohepatitis (NASH) and Prader Willi syndrome (PWS), an orphan disease, and anti-psychotic drug induced weight gain (AIWG). The company was founded by Jay Edward Birnbaum and is headquartered San Diego, CA. | - |
Feng-Yu Lee | F | - |
Hallux, Inc.
Hallux, Inc. Pharmaceuticals: MajorHealth Technology Hallux, Inc. provides pharmaceutical services. It develops a new terbinafine dosage form and subungual route of administration for the treatment of onychomycosis. The company was founded by Mark T. Taylor, Jay Edward Birnbaum, Hendrik Arend Kroon and Robert Orr in 2012 and is headquartered in Laguna Hills, CA. | - |
Seth M. Birnbaum | M | - |
Hallux, Inc.
Hallux, Inc. Pharmaceuticals: MajorHealth Technology Hallux, Inc. provides pharmaceutical services. It develops a new terbinafine dosage form and subungual route of administration for the treatment of onychomycosis. The company was founded by Mark T. Taylor, Jay Edward Birnbaum, Hendrik Arend Kroon and Robert Orr in 2012 and is headquartered in Laguna Hills, CA. | 2 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
James J. Schutz | M | 61 | 15 years | |
Robert E. Miller | M | 82 | 14 years | |
Hojabr Alimi | M | 62 | 15 years | |
Frederick J. Sandford | M | 63 | 1 years | |
Gregg Alton | M | 58 | 5 years | |
Gregory M. French | M | 62 | 14 years | |
Marc Umscheid | M | 55 | 2 years | |
Hendrik Arend Kroon | M | - |
Hallux, Inc.
Hallux, Inc. Pharmaceuticals: MajorHealth Technology Hallux, Inc. provides pharmaceutical services. It develops a new terbinafine dosage form and subungual route of administration for the treatment of onychomycosis. The company was founded by Mark T. Taylor, Jay Edward Birnbaum, Hendrik Arend Kroon and Robert Orr in 2012 and is headquartered in Laguna Hills, CA. | 5 years |
Sharon Barbari | F | 70 | 7 years | |
Russell J. Harrison | M | 79 | 4 years | |
Richard K. Conley | M | 73 | 15 years | |
Michael G. Wokasch | M | - | 2 years | |
Dana Redhair | M | - | - | |
Robert Burlingame | M | 90 | 4 years | |
Robert Northey | M | 67 | 15 years | |
Robert Edwards | M | 46 | - | |
Chad White | M | 51 | 1 years | |
Jeffrey S. Day | M | - | - |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 37 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Jay Birnbaum
- Personal Network